免疫相关肿瘤反应标准和接受依匹单抗治疗患者免疫相关不良事件模式的放射学特征。
Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
机构信息
Department of Radiology, Dana-Farber Cancer Institute and Melanoma Disease Center, Dana-Farber/Brigham and Women's Cancer Center, 44 Binney St, Boston, MA 02115, USA.
出版信息
AJR Am J Roentgenol. 2011 Aug;197(2):W241-6. doi: 10.2214/AJR.10.6032.
OBJECTIVE
The objective of this article is to illustrate examples of radiologic immune-related response criteria and toxicity in patients with advanced melanoma treated with the immunotherapeutic agent ipilimumab.
CONCLUSION
Novel immune-related tumor response criteria should be applied to patients undergoing therapy with ipilimumab for advanced melanoma. Ipilimumab also produces a spectrum of immune-related adverse effects that can be recognized radiologically.
目的
本文旨在举例说明接受免疫治疗药物伊匹单抗治疗的晚期黑色素瘤患者的影像学免疫相关反应标准和毒性。
结论
对于接受伊匹单抗治疗的晚期黑色素瘤患者，应采用新型免疫相关肿瘤反应标准。伊匹单抗还会产生一系列可在影像学上识别的免疫相关不良反应。
Zotero 插件